NuCana (NCNA) 6-K NuCana Receives Positive Opinion for Orphan Drug Designation in the European

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE13a-16 OR15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2020

(Commission FileNo. 001-38215)

NUCANA PLC

(Translation of registrant’s name into English)

3 Lochside Way

Edinburgh EH12 9DT

United Kingdom

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under coverForm 20-F orForm 40-F.

Form 20-F  ☒            Form40-F  ☐

Indicate by check mark if the registrant is submitting theForm 6-K in paper as permitted by RegulationS-T Rule 101 (b) (1):  ☐

Indicate by check mark if the registrant is submitting theForm 6-K in paper as permitted by RegulationS-T Rule 101 (b) (7):  ☐

Other Events

On March 4, 2020, NuCana plc (the “Company”) issued a press release announcing that the European Medicines Agency’s Committee for Orphan Medicinal Products has issued a positive opinion for orphan drug designation of Acelarin for the treatment of patients with biliary tract cancer. The press release is attached as Exhibit 99.1 and is incorporated by reference herein.

The press release attached as Exhibit 99.1 and incorporated by reference herein is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Exhibits

Exhibit	Description
99.1	Press Release dated March 4, 2020

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NuCana plc
By:	/s/ Donald Munoz
Name:	Donald Munoz
Title:	Chief Financial Officer

Date: March 4, 2020